Cabozantinib for the treatment of kidney cancer

被引：50

作者：

Abdelaziz, Ahmed ^{[1
]}

Vaishampayan, Ulka ^{[1
]}

机构：

[1] Wayne State Univ, Dept Oncol, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2017年 / 17卷 / 07期

关键词：

Cabozantinib; renal cell carcinoma; targeted therapy; RCC; METEOR; MET; CABOSUN; RENAL-CELL CARCINOMA; POTENTIAL THERAPEUTIC TARGET; KINASE INHIBITOR; DOUBLE-BLIND; OPEN-LABEL; HGF/C-MET; PHASE-III; PHARMACOKINETICS; EVEROLIMUS; SUNITINIB;

D O I：

10.1080/14737140.2017.1344553

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy.Areas covered: In the METEOR trial, cabozantinib demonstrated significantly improved efficacy in all three endpoints; response rates, progression free survival and overall survival in a randomized trial with everolimus as an active comparator. Cabozantinib also showed activity in the front line setting in RCC within the CABOSUN trial. The study randomized untreated metastatic RCC patients to either cabozantinib or sunitinib and the former showed improved progression free survival which was the primary endpoint. The future holds promise for indications in other malignancies, given the preliminary efficacy and unique mechanism of action of cabozantinib.In this review we address the mechanism of action, pharmacodynamics and pharmacokinetics of cabozantinib, and also review the development pathway of this agent in the treatment of advanced renal cell carcinoma. The potential benefit in specific patient populations, such as poor risk patients and bone metastases subgroups is also discussed.Expert commentary: The clinical applications of cabozantinib will be addressed within the context of the current competitive therapeutic landscape of RCC.

引用

页码：577 / 584

页数：8

共 42 条

[1]

[Anonymous], ASCO MEETING ABSTRAC

[2]

[Anonymous], J CLIN ONCOL

[3]

[Anonymous], 2012, COM CAB CAPS US PRES

[4] In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer [J].

Bentzien, Frauke ;

Zuzow, Marcus ;

Heald, Nathan ;

Gibson, Anna ;

Shi, Yongchang ;

Goon, Leanne ;

Yu, Peiwen ;

Engst, Stefan ;

Zhang, Wentao ;

Huang, Donghui ;

Zhao, Lora ;

Vysotskaia, Valentina ;

Chu, Felix ;

Bautista, Rajana ;

Cancilla, Belinda ;

Lamb, Peter ;

Joly, Alison H. ;

Yakes, F. Michael .

THYROID, 2013, 23 (12) :1569-1577

[5] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[6] A phase I study of cabozantinib (XL184) in patients with renal cell cancer [J].

Choueiri, T. K. ;

Pal, S. K. ;

McDermott, D. F. ;

Morrissey, S. ;

Ferguson, K. C. ;

Holland, J. ;

Kaelin, W. G. ;

Dutcher, J. P. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1603-1608

[7] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial [J].

Choueiri, Toni K. ;

Halabi, Susan ;

Sanford, Ben L. ;

Hahn, Olwen ;

Michaelson, M. Dror ;

Walsh, Meghara K. ;

Feldman, Darren R. ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

George, Daniel J. ;

Morris, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :591-+

[8] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial [J].

Choueiri, Toni K. ;

Escudier, Bernard ;

Powles, Thomas ;

Tannir, Nizar M. ;

Mainwaring, Paul N. ;

Rini, Brian I. ;

Hammers, Hans J. ;

Donskov, Frede ;

Roth, Bruce J. ;

Peltola, Katriina ;

Lee, Jae Lyun ;

Heng, Daniel Y. C. ;

Schmidinger, Manuela ;

Agarwal, Neeraj ;

Sternberg, Cora N. ;

McDermott, David F. ;

Aftab, Dana T. ;

Hessel, Colin ;

Old, Christian Scheff ;

Schwab, Gisela ;

Hutson, Thomas E. ;

Pal, Sumanta ;

Motzer, Robert J. .

LANCET ONCOLOGY, 2016, 17 (07) :917-927

[9] Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models [J].

Ciamporcero, Eric ;

Miles, Kiersten Marie ;

Adelaiye, Remi ;

Ramakrishnan, Swathi ;

Shen, Li ;

Ku, ShengYu ;

Pizzimenti, Stefania ;

Sennino, Barbara ;

Barrera, Giuseppina ;

Pili, Roberto .

MOLECULAR CANCER THERAPEUTICS, 2015, 14 (01) :101-110

[10] Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective [J].

Corso, Simona ;

Giordano, Silvia .

CANCER DISCOVERY, 2013, 3 (09) :978-992

← 1 2 3 4 5 →